RIGL.US Rigel Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
42.92 USD
Close of Nov 18, 2026
24.95 52.61
Market cap
USD 808M
P/E
2.7x
P/B
1.85x
ROE
11.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RIGL.US undervalued?

Graham number
Price42.92
Graham value90.84
Discount52.7%

RIGL.US trades 52.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rigel Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Rigel Pharmaceuticals Inc yet.

Rigel Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitra…

Full company profile